---

 

		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)

October 22, 2004

 

 

CELL THERAPEUTICS, INC

(Exact name of registrant as specified in its charter)

 

 

Washington		0-28386		91-1533912
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

 

501 Elliott Avenue West, Suite 400 Seattle, Washington		98119
(Address of principal executive offices)		(Zip Code)

 

 

Registrant’s telephone number, including area code

(206) 282-7100

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

---

Item 8.01. Other Events.

 

On October 22, 2004, Cell Therapeutics, Inc. (the “Company”) received payment in full, including all accrued interest, on that certain $3.5 million loan extended by the Company to Dr. James A. Bianco in April 2002.

 

-1-

---

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		CELL THERAPEUTICS, INC.
Date: October 22, 2004		By:		/s/ Louis A. Bianco
				Louis A. Bianco
				Executive Vice President, Finance and Administration (Principal Accounting Officer)